Targeted Drug Delivery in Brain Tumor Microenvironments
A Special Issue of Pharmaceutics (ISSN 1999-4923) belonging to the section "Drug Delivery and Controlled Release".
Deadline for manuscript submissions: 30 November 2026 | Viewed by 1840
Editors
Interests: glioblastomas; brain drug delivery; nanomedicine; preclinical model; drug repurposing; surgery; tumour microenvironment
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Consideration of the brain tumour microenvironment is gaining momentum in the neuro-oncology field. The microenvironment is a complex ecosystem consisting of many cell types, such as astrocytes, neurons, microglia and immune cells, which we understand play a role in tumour development and progression.
Many drug delivery techniques are in development for brain tumours due to their poor prognosis and their barriers to treatment, such as the blood brain barrier, off-target toxicity and tumour heterogeneity. These drug delivery systems are now becoming more targeted against both brain tumour cells and the local microenvironment.
This Special Issue will address new developments in the area of targeted drug delivery for brain tumours. We invite articles on all classifications of brain tumours, looking at both the systemic and local delivery of therapeutics that target the tumour and/or its microenvironment. Original research papers and review articles are welcome.
Dr. Chiara Bastiancich
Dr. Phoebe McCrorie
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-anonymized peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- neuro-oncology
- drug delivery
- tumour microenvironment
- targeted drug delivery
- glioblastoma
- medulloblastoma
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
